	US 12,303,547 B2
	Compound, use, pharmaceutical composition, method of diagnosis, method of treatment, and method of transportation and/or internalization of a compound into eukaryotic cells
Ana Marisa Chudzinski Tavassi, SãPaulo (BR); Miryam Paola Alvarez-Flores, Säo Paulo (BR); Katia Luciano Pereira Morais, Säo Paulo (BR); Gilles Mourier, Villebon-sur-Yvette (FR); and Denis Servent, Gif sur Yvette (FR)
Assigned to INSTITUTO BUTANTAN, São Paulo (BR)
Appl. No. 17/309,373
Filed by INSTITUTO BUTANTAN, São Paulo (BR)
PCT Filed Nov. 22, 2019, PCT No. PCT/BR2019/050501 § 371(c)(1), (2) Date May 21, 2021, PCT Pub. No. WO2020/102874, PCT Pub. Date May 28, 2020.
Claims priority of application No. 102018074037-7 (BR), filed on Nov. 22, 2018.
Prior Publication US 2022/0088122 A1, Mar. 24, 2022
Int. Cl. A61K 38/17 (2006.01); A61K 38/10 (2006.01); A61K 47/60 (2017.01)

CPC A61K 38/17 (2013.01) [A61K 38/10 (2013.01); A61K 47/60 (2017.08)]

11 Claims

1. A compound comprising the peptide as defined in SEQ ID NO: 3 or SEQ ID NO:5, wherein the compound lacks a Kunitz domain, and wherein the compound is chemically bonded or fused to an active pharmaceutical ingredient other than a Kunitz domain.